Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

NCT02175602 ·Status: COMPLETED ·Phase: PHASE1

Evaluate Severe Hepatic Impairment on Dacomitinib PK

NCT03865446 ·Status: COMPLETED ·Phase: PHASE1

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

NCT01512693 ·Status: COMPLETED ·Phase: PHASE1

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

NCT04193436 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

NCT04867941 ·Status: COMPLETED ·Phase: PHASE1

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996 ·Status: COMPLETED ·Phase: PHASE1

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

NCT01763190 ·Status: COMPLETED ·Phase: PHASE1

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT02474537 ·Status: COMPLETED ·Phase: PHASE1

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

NCT00859053 ·Status: COMPLETED ·Phase: PHASE1

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

NCT02039817 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

NCT03289208 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine

NCT02184091 ·Status: COMPLETED ·Phase: PHASE1

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

NCT04604496 ·Status: COMPLETED ·Phase: PHASE1

Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects

NCT02045966 ·Status: COMPLETED ·Phase: PHASE1

Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

NCT01901133 ·Status: COMPLETED ·Phase: PHASE1

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

NCT00831532 ·Status: COMPLETED ·Phase: PHASE1

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

NCT02121860 ·Status: COMPLETED ·Phase: PHASE1

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

NCT04166942 ·Status: COMPLETED ·Phase: PHASE1

Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

NCT06928779 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

NCT01370148 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

NCT02135302 ·Status: COMPLETED ·Phase: PHASE1

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

NCT02256033 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

NCT02245243 ·Status: COMPLETED ·Phase: PHASE1

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

NCT04091061 ·Status: COMPLETED ·Phase: PHASE1

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

NCT04831944 ·Status: COMPLETED ·Phase: PHASE1